Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12.
Saved in:
| Title: | Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12. |
|---|---|
| Authors: | Kurokawa C; Virology and Vaccine Discovery, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Agrawal S; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Mitra A; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Galvani E; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Cambridge, UK., Burke S; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Cambridge, UK., Varshine A; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Rothstein R; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Schifferli K; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Monks NR; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Foloppe J; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Silvestre N; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Quemeneur E; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Demeusoit C; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Kleinpeter P; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Sapra P; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Barrett C; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Hammond SA; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Kelly EJ; Clinical Virology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Laliberte J; Virology and Vaccine Discovery, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Durham NM; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Oberst M; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Broggi MAS; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA. |
| Source: | Molecular therapy. Oncology [Mol Ther Oncol] 2024 Jan 10; Vol. 32 (1), pp. 200758. Date of Electronic Publication: 2024 Jan 10 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 9918752083706676 Publication Model: eCollection Cited Medium: Print ISSN: 2950-3299 (Print) Linking ISSN: 29503299 NLM ISO Abbreviation: Mol Ther Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38596304 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Kurokawa+C%22">Kurokawa C</searchLink>; Virology and Vaccine Discovery, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Agrawal+S%22">Agrawal S</searchLink>; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Mitra+A%22">Mitra A</searchLink>; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Galvani+E%22">Galvani E</searchLink>; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Burke+S%22">Burke S</searchLink>; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Varshine+A%22">Varshine A</searchLink>; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Rothstein+R%22">Rothstein R</searchLink>; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Schifferli+K%22">Schifferli K</searchLink>; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Monks+NR%22">Monks NR</searchLink>; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Foloppe+J%22">Foloppe J</searchLink>; Department of Research, Transgene SA, Illkirch-Graffenstaden, France.<br /><searchLink fieldCode="AU" term="%22Silvestre+N%22">Silvestre N</searchLink>; Department of Research, Transgene SA, Illkirch-Graffenstaden, France.<br /><searchLink fieldCode="AU" term="%22Quemeneur+E%22">Quemeneur E</searchLink>; Department of Research, Transgene SA, Illkirch-Graffenstaden, France.<br /><searchLink fieldCode="AU" term="%22Demeusoit+C%22">Demeusoit C</searchLink>; Department of Research, Transgene SA, Illkirch-Graffenstaden, France.<br /><searchLink fieldCode="AU" term="%22Kleinpeter+P%22">Kleinpeter P</searchLink>; Department of Research, Transgene SA, Illkirch-Graffenstaden, France.<br /><searchLink fieldCode="AU" term="%22Sapra+P%22">Sapra P</searchLink>; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Barrett+C%22">Barrett C</searchLink>; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Hammond+SA%22">Hammond SA</searchLink>; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Kelly+EJ%22">Kelly EJ</searchLink>; Clinical Virology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Laliberte+J%22">Laliberte J</searchLink>; Virology and Vaccine Discovery, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Durham+NM%22">Durham NM</searchLink>; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Oberst+M%22">Oberst M</searchLink>; Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Broggi+MAS%22">Broggi MAS</searchLink>; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229918752083706676%22">Molecular therapy. Oncology</searchLink> [Mol Ther Oncol] 2024 Jan 10; Vol. 32 (1), pp. 200758. <i>Date of Electronic Publication: </i>2024 Jan 10 (<i>Print Publication: </i>2024). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%22">Elsevier Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9918752083706676 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2950-3299 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2229503299%22">29503299 </searchLink><i>NLM ISO Abbreviation: </i>Mol Ther Oncol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38596304 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.omton.2023.200758 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 200758 Titles: – TitleFull: Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Kurokawa C – PersonEntity: Name: NameFull: Agrawal S – PersonEntity: Name: NameFull: Mitra A – PersonEntity: Name: NameFull: Galvani E – PersonEntity: Name: NameFull: Burke S – PersonEntity: Name: NameFull: Varshine A – PersonEntity: Name: NameFull: Rothstein R – PersonEntity: Name: NameFull: Schifferli K – PersonEntity: Name: NameFull: Monks NR – PersonEntity: Name: NameFull: Foloppe J – PersonEntity: Name: NameFull: Silvestre N – PersonEntity: Name: NameFull: Quemeneur E – PersonEntity: Name: NameFull: Demeusoit C – PersonEntity: Name: NameFull: Kleinpeter P – PersonEntity: Name: NameFull: Sapra P – PersonEntity: Name: NameFull: Barrett C – PersonEntity: Name: NameFull: Hammond SA – PersonEntity: Name: NameFull: Kelly EJ – PersonEntity: Name: NameFull: Laliberte J – PersonEntity: Name: NameFull: Durham NM – PersonEntity: Name: NameFull: Oberst M – PersonEntity: Name: NameFull: Broggi MAS IsPartOfRelationships: – BibEntity: Dates: – D: 10 M: 01 Text: 2024 Jan 10 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 2950-3299 Numbering: – Type: volume Value: 32 – Type: issue Value: 1 Titles: – TitleFull: Molecular therapy. Oncology Type: main |
| ResultId | 1 |